Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01581632 · ClinicalTrials.gov registry record · Phase 1
Assessment of Coronary Plaque Composition
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT01581632: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01581632 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01581632, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The investigators' hypothesis is that local activation of the endogenous Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays an integral role in early atherosclerosis, and contributes to the mechanism of coronary endothelial dysfunction and to the structural and mechanical properties that characterize plaque vulnerability. Thus, this study will characterize prospectively the correlation between the functional and structural vascular wall properties, and the activity of the Lp-PLA2 pathway.
Interventions
- DEVICE LipiScan/LipiScan IVUS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2010-01 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01581632
The ClinicalTrials.gov registry entry for NCT01581632 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LipiScan/LipiScan IVUS is the first listed.
NCT01581632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01581632 about?
NCT01581632 is a clinical study titled "Assessment of Coronary Plaque Composition". The investigators' hypothesis is that local activation of the endogenous Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays an integral role in early atherosclerosis, and contributes to the mechanism of coronary endothelial dysfunction and to the structural and mechanical properties that charac...
What is the current status of trial NCT01581632?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2010-01. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01581632?
The interventions under investigation include: LipiScan/LipiScan IVUS (DEVICE).
Who is sponsoring clinical trial NCT01581632?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.